1. The Role of TRAIL/DRs in the Modulation of Immune Cells and Responses
   Duygu Sag et al, 2019, Cancers CrossRef
2. MAOA suppresses the growth of gastric cancer by interacting with NDRG1 and regulating the Warburg effect through the PI3K/AKT/mTOR pathway
   Yang-Yang Wang et al, 2023, Cellular Oncology CrossRef
3. TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy
   Adam S. Dayoub et al, 2020, Cell Communication and Signaling CrossRef
4. Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential
   Reem Saleh et al, 2020, Expert Opinion on Therapeutic Targets CrossRef
5. Bacteria‐derived ferrichrome inhibits tumor progression in sporadic colorectal neoplasms and colitis‐associated cancer
   Takuya Iwama et al, 2021, Cancer Cell International CrossRef
6. A risk score system based on DNA methylation levels and a nomogram survival model for lung squamous cell carcinoma
   Ming Zhang et al, 2020, International Journal of Molecular Medicine CrossRef
7. TIM-3 pathway dysregulation and targeting in cancer
   Amer M Zeidan et al, 2021, Expert Review of Anticancer Therapy CrossRef
8. DR4 mediates the progression, invasion, metastasis and survival of colorectal cancer through the Sp1/NF1 switch axis on genomic locus
   Shenshen Wu et al, 2018, International Journal of Cancer CrossRef
9. Probiotics Based Anticancer Immunity In Stomach Cancer
   Shilpi Singh et al, 2023, Probiotics in Anticancer Immunity CrossRef
10. The Janus Face of Death Receptor Signaling during Tumor Immunoediting
    Eimear O’ Reilly et al, 2016, Frontiers in Immunology CrossRef
11. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel
    L. Sams et al, 2021, Clinical and Translational Oncology CrossRef
12. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
    Letong Cai et al, 2023, Journal of Hematology & Oncology CrossRef